Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
SAN DIEGO, Oct. 31, 2017 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced today that it will report its third quarter financial and operating results after the close of U.S. financial markets on Tuesday, November 7, 2017. In addition, management will host a conference call to provide an update on corporate activities and discuss the quarterly financial results.
| Conference call and webcast: | |
| Date: | November 7, 2017 |
| Time: | 4:30 pm Eastern Time (1:30 pm Pacific Time) |
| Dial-in: | (855) 779-9066 (Domestic) or (631) 485-4859 (International) |
| Passcode: | 7458759 |
| Via web: | www.traconpharma.com; “Events and Presentation” section within the “Investors” section |
A replay of the webcast will be available for 60 days on the website.
About TRACON
TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma; and TRC253, a small molecule that is being developed for the treatment of prostate cancer. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
Company Contact:
Casey Logan
Chief Business Officer
(858) 550-0780 ext. 236
[email protected]
Investor Contact:
Andrew McDonald
LifeSci Advisors LLC
646-597-6987
[email protected]
